← Browse by Condition
Medical Condition
pulmonary arterial hypertension pah
Total Trials
8
Recruiting Now
8
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 2
Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.
Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.
Frequently Asked Questions — pulmonary arterial hypertension pah Clinical Trials
How many clinical trials are currently recruiting for pulmonary arterial hypertension pah?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for pulmonary arterial hypertension pah, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pulmonary arterial hypertension pah?
pulmonary arterial hypertension pah research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pulmonary arterial hypertension pah clinical trial?
Eligibility criteria for pulmonary arterial hypertension pah trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 2
Phase 3 1
Phase 4 1
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06917196
Recruiting
Enrollment
16 pts
Location
Italy
Sponsor
Fondazione IRCCS Policlinico S...
NCT07593027 Phase 1, Phase 2
Recruiting
Enrollment
120 pts
Location
China
Sponsor
ImmuneCare Biopharmaceuticals ...
NCT06968962
Recruiting
Enrollment
376 pts
Location
China
Sponsor
Second Affiliated Hospital, Zh...
NCT07245680 Phase 3
Recruiting
Enrollment
186 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
NCT07318597 Phase 2
Recruiting
Enrollment
99 pts
Location
United States, Austr...
Sponsor
Regeneron Pharmaceuticals
NCT06865118
Recruiting
Enrollment
20 pts
Location
Norway
Sponsor
Oslo University Hospital
NCT07713914 Phase 4
Recruiting
Enrollment
196 pts
Location
Brazil
Sponsor
University of Sao Paulo Genera...
NCT06850792
Recruiting
Enrollment
61 pts
Location
Brazil
Sponsor
University of Sao Paulo Genera...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology